Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China.

Abstract

BACKGROUND:

Understanding the impact of drug exposure and susceptibility on treatment response of multidrug-resistant tuberculosis (MDR-TB) will help to optimise treatment. This study aimed to investigate the association between drug exposure, susceptibility and response to MDR-TB treatment.

METHODS:

Drug exposure and susceptibility for second-line drugs were measured for patients with MDR-TB. Multivariate analysis was applied to investigate the impact of drug exposure and susceptibility on sputum culture conversion and treatment outcome. Probability of target attainment was evaluated. Random Forest and CART (Classification and Regression Tree) analysis was used to identify key predictors and their clinical targets among patients on World Health Organization-recommended regimens.

RESULTS:

Drug exposure and corresponding susceptibility were available for 197 patients with MDR-TB. The probability of target attainment was highly variable, ranging from 0% for ethambutol to 97% for linezolid, while patients with fluoroquinolones above targets had a higher probability of 2-month culture conversion (56.3% versus 28.6%; adjusted OR 2.91, 95% CI 1.42-5.94) and favourable outcome (88.8% versus 68.8%; adjusted OR 2.89, 95% CI 1.16-7.17). Higher exposure values of fluoroquinolones, linezolid and pyrazinamide were associated with earlier sputum culture conversion. CART analysis selected moxifloxacin area under the drug concentration-time curve/minimum inhibitory concentration (AUC0-24h/MIC) of 231 and linezolid AUC0-24h/MIC of 287 as best predictors for 6-month culture conversion in patients receiving identical Group A-based regimens. These associations were confirmed in multivariate analysis.

CONCLUSIONS:

Our findings indicate that target attainment of TB drugs is associated with response to treatment. The CART-derived thresholds may serve as targets for early dose adjustment in a future randomised controlled study to improve MDR-TB treatment outcome.

• Authors: Xubin Zheng, Lina Davies Forsman, Ziwei Bao, Yan Xie, Zhu Ning, Thomas Schön, Judith Bruchfeld, Biao Xu, Jan-Willem Alffenaar, Yi Hu
• Journal: The European respiratory journal (Eur Respir J) Vol. 59 Issue 3 (Mar 2022) ISSN: 1399-3003 [Electronic] England
• PMID: 34737224 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright ©The authors 2022.

Chemical References

• Antitubercular Agents
• Pyrazinamide

Topics

• Antitubercular Agents (adverse effects)
• Humans
• Microbial Sensitivity Tests
• Mycobacterium tuberculosis
• Prospective Studies
• Pyrazinamide (adverse effects)
• Treatment Outcome
• Tuberculosis, Multidrug-Resistant (drug therapy)